Reversible	reversible	O	O
cholestasis	cholestasis	O	S_disease
with	with	O	O
bile	bile	O	O
duct	duct	O	O
injury	injury	O	O
following	following	O	O
azathioprine	azathioprine	S_chemical	O
therapy	therapy	O	O
.	.	O	O

A	a	O	O
case	case	O	O
report	report	O	O
.	.	O	O

A	a	O	O
67-year-old	67-year-old	O	O
patient	patient	O	O
,	,	O	O
with	with	O	O
primary	primary	O	O
polymyositis	polymyositis	O	O
and	and	O	O
without	without	O	O
previous	previous	O	O
evidence	evidence	O	O
of	of	O	O
liver	liver	O	B_disease
disease	disease	O	I_disease
,	,	O	O
developed	developed	O	O
clinical	clinical	O	O
and	and	O	O
biochemical	biochemical	O	O
features	features	O	O
of	of	O	O
severe	severe	O	O
cholestasis	cholestasis	O	S_disease
3	3	O	O
months	months	O	O
after	after	O	O
initiation	initiation	O	O
of	of	O	O
azathioprine	azathioprine	S_chemical	O
therapy	therapy	O	O
.	.	O	O

Liver	liver	O	O
biopsy	biopsy	O	O
showed	showed	O	O
cholestasis	cholestasis	O	S_disease
with	with	O	O
both	both	O	O
cytological	cytological	O	O
and	and	O	O
architectural	architectural	O	O
alterations	alterations	O	O
of	of	O	O
interlobular	interlobular	O	O
bile	bile	O	O
ducts	ducts	O	O
.	.	O	O

Azathioprine	azathioprine	S_chemical	O
withdrawal	withdrawal	O	O
resulted	resulted	O	O
after	after	O	O
7	7	O	O
weeks	weeks	O	O
in	in	O	O
the	the	O	O
resolution	resolution	O	O
of	of	O	O
clinical	clinical	O	O
and	and	O	O
biochemical	biochemical	O	O
abnormalities	abnormalities	O	O
.	.	O	O

It	it	O	O
is	is	O	O
believed	believed	O	O
that	that	O	O
this	this	O	O
is	is	O	O
the	the	O	O
first	first	O	O
reported	reported	O	O
case	case	O	O
of	of	O	O
reversible	reversible	O	O
azathioprine-induced	azathioprine-induced	O	O
cholestasis	cholestasis	O	S_disease
associated	associated	O	O
with	with	O	O
histological	histological	O	O
evidence	evidence	O	O
of	of	O	O
bile	bile	O	O
duct	duct	O	O
injury	injury	O	O
.	.	O	O

